on 10 Jan 2024
Last Applicant/ Owned by
5555 OBERLIN DRIVE, SUITE 120
SAN DIEGO
CA
92121
Serial Number
97442171 filed on 03rd Jun 2022
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
scientific research and development; Scientific research and development in the pharmaceutical and biotechnology fields; research and development of new technology in the field of gene therapy, genome writing, genome engineering, engineered HSV vector; scientific testing, inspection, research, and development of pharmaceutical preparations for gene therapy; scientific research and development of a Read More
scientific research and development; Scientific research and development in the pharmaceutical and biotechnology fields; research and development of new technology in the field of gene therapy, genome writing, genome engineering, engineered HSV vector; scientific testing, inspection, research, and development of pharmaceutical preparations for gene therapy; scientific research and development of a hypoimmunogenic cell for purposes of providing cell therapy; research and development of new technology in the field of cell therapy; scientific testing, inspection, research, and development of pharmaceutical preparations for cell therapy
Pharmaceutical preparations for cell therapy to treat human diseases and disorders; cell therapy products, namely, pharmaceutical preparations to treat cellular disorders, namely, human diseases and disorders
No 97442171
No Service Mark
No 62600-TM1011
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
10th Jan 2024 | ABANDONMENT - AFTER PUBLICATION |
10th Jan 2024 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION |
09th Jan 2024 | TEAS EXPRESS ABANDONMENT RECEIVED |
21st Aug 2023 | EXTENSION OF TIME TO OPPOSE RECEIVED |
08th Aug 2023 | PUBLISHED FOR OPPOSITION |
08th Aug 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
19th Jul 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
03rd Jul 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
30th Jun 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
29th Jun 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |